CIISA, Faculdade de Medicina Veterinária, Universidade Técnica de Lisboa, Av. da Universidade Técnica, 1300-477 Lisboa, Portugal.
Microsc Microanal. 2013 Aug;19(4):876-82. doi: 10.1017/S1431927613001529. Epub 2013 May 30.
Human epidermal growth factor receptor (HER2) is a tumor biomarker that when overexpressed and/or amplified is associated with a poor prognosis for women with breast cancer. This specific tumor subtype is eligible for a specific immunotherapy that increases survival period. However, in feline oncology, only a few studies have been performed on molecular characterization of feline (fHER2) in feline mammary carcinoma (FMC), and the available data are inconsistent. In this study, fHER2 protein levels and gene status in FMC were evaluated by immunohistochemistry and in situ hybridization. After being optimized, these techniques revealed that fHER2 is overexpressed in 33% of FMC cases, although fHER2 and fTOP2A gene amplification could not be observed. Our results support the possibility of using FMC as a natural model for comparative oncology. Additional data obtained may also improve the diagnostics, and consequently the treatment, of this type of tumor in veterinary medicine.
人表皮生长因子受体 (HER2) 是一种肿瘤生物标志物，当其过度表达和/或扩增时，与乳腺癌女性的预后不良相关。这种特定的肿瘤亚型有资格接受一种特定的免疫疗法，该疗法可延长生存期。然而，在猫科肿瘤学中，仅有少数研究针对猫科表皮生长因子受体 (fHER2) 在猫乳腺肿瘤 (FMC) 中的分子特征进行了研究，并且可用数据不一致。在这项研究中，通过免疫组织化学和原位杂交评估了 FMC 中的 fHER2 蛋白水平和基因状态。在经过优化后，这些技术显示 fHER2 在 33%的 FMC 病例中过度表达，尽管未能观察到 fHER2 和 fTOP2A 基因扩增。我们的研究结果支持将 FMC 用作比较肿瘤学的天然模型的可能性。获得的其他数据也可能改善兽医肿瘤学中这种肿瘤的诊断和治疗。
